Novartis gene therapy would be cost effective up to $900,000: U.S. group

(Reuters) – An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.

FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann

The Boston-based Institute for Clinical and Economic Review (ICER) made the determination using a commonly cited cost-effectiveness threshold that values each “quality-adjusted life year” (QALY) gained at $100,000 to $150,000.

If each QALY gained were assessed at $500,000, ICER found the gene therapy, Zolgensma, would be cost effective at just over $5 million.

Novartis has said the price will be determined in negotiations with health plans, but it believes the gene therapy would be cost effective at $4 million to $5 million as a one-time treatment.

The company said in an emailed statement on Friday that “both the rare disease community and various governmental bodies” suggest that $500,000 per QALY “is the appropriate standard to protect vulnerable populations and allow access to innovative, transformational therapies.”

SMA can lead to paralysis, breathing difficulty and death. It is the leading genetic cause of death in infants.

Gene therapies use engineered viruses to carry healthy genetic material into a person’s cells to replace faulty or mutated genes that cause a disease or condition.

ICER also found that Spinraza, Biogen Inc’s SMA treatment would require a substantial price decrease to be considered cost effective. Spinraza’s current list price is $750,000 for the initial year and $375,000 per year thereafter.

Biogen noted that Zolgensma is experimental and has reported data for only 15 patients, compared with Spinraza’s track record of use by more than 6,600 patients. Spinraza is considered by Wall Street to be one of Biogen’s most important growth drivers.

“The promise of gene therapy in general is that it would be once and done … but that is uncertain at this point,” Biogen Chief Medical Officer Alfred Sandrock told Reuters.

“Spinraza is still a very viable option for babies with SMA. For children, teenagers and adults it may be the only option open to them,” Sandrock said.

Spinraza was approved in 2016 to treat SMA in children and adults.

The U.S. Food and Drug Administration is expected to decide sometime in May whether to approve Zolgensma, which has been studied in infants with SMA.

ICER’s assessments have become increasingly influential in U.S. drug price negotiations and are taken into consideration by insurers making decisions about patient access to treatments.

Using an alternate measure known as “life years gained” (LYG), ICER found the Novartis gene therapy cost effective at a price as high as $1.5 million.

ICER found that Spinraza, when used for patients who do not yet show symptoms, would have value at up to $130,000 for the first year and $65,000 for each successive year. Based on the LYG measurement, the price could be as high as $82,000 during the initial year and $41,000 per year thereafter, according to the ICER report.

At the QALY value of $500,000, Spinraza was seen by ICER as cost-effective at $264,000 per year.

Reporting By Deena Beasley; Editing by Bill Berkrot

Source

more recommended stories

  • Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 million

    (Reuters) – Bayer AG and Johnson.

  • Texas petrochemical fire prompts hundreds to visit health clinic

    DEER PARK, Texas (Reuters) – Hundreds.

  • U.S. Customs details China pork seizure; importers could pay fine

    CHICAGO (Reuters) – U.S. border agents.

  • FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

    (Reuters) – The U.S. Food and.

  • Tyson recalls tons of chicken strips for possible metal contamination

    (Reuters) – Tyson Foods Inc is.

  • Mississippi governor signs ‘heartbeat’ abortion ban

    (Reuters) – Mississippi’s Republican governor signed.

  • Congo Ebola outbreak spreads to city of Bunia

    GOMA, Democratic Republic of Congo (Reuters).

  • Second U.S. jury finds Bayer’s Roundup caused cancer

    (Reuters) – A U.S. jury on.

  • Soda, sports drinks tied to higher risk of early death

    (Reuters Health) – People who consume.

  • Apple Watch detects irregular heart beat in large U.S. study

    (Reuters) – The Apple Watch was.

  • Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

    (Reuters) – Non-invasive heart valve replacement.

  • U.S. seizes 1 million pounds of pork from China on swine fever concerns

    WASHINGTON (Reuters) – U.S. border agents.

  • Teen drivers reaching for objects more likely to crash

    (Reuters Health) – Teen drivers who.

  • Quality of surgical care across a hospital network may vary

    (Reuters Health) – Just because the.

  • California jury awards $29 million to woman with cancer who used J&J talc

    (Reuters) – A California jury on.

  • As wildfires devour communities, toxic threats emerge

    PARADISE, Calif. (Reuters) – As an.

  • Court allows Ohio law blocking Planned Parenthood funding

    FILE PHOTO: A sign is pictured.

  • FDA approves Pfizer’s biosimilar to Roche’s Herceptin

    FILE PHOTO: The logo of U.S..

  • Mumps, other outbreaks force U.S. detention centres to quarantine over 2,000 migrants

    (Reuters) – Christian Mejia thought he.

  • Measles outbreak in New Zealand’s Canterbury widens to 20

    MELBOURNE (Reuters) – Thousands of vaccines.

  • OxyContin maker Purdue Pharma loses bid to delay opioid epidemic trial

    (Reuters) – OxyContin maker Purdue Pharma.

  • Roche’s Tecentriq wins U.S. approval for aggressive breast cancer

    FILE PHOTO: The logo of Swiss.

  • Knee surgery for torn cartilage may not be worthwhile

    (Reuters Health) – Many middle-aged and.

  • FDA finds asbestos in three Claire’s cosmetics products

    (Reuters) – The U.S. Food and.

  • J&J nasal spray gets U.S. approval as first new type of anti-depressant in decades

    (Reuters) – The U.S. Food and.

  • London HIV patient becomes world’s second AIDS cure hope

    LONDON, March 4 (Reuters) – An.

  • Eli Lilly seeks to quell drug price anger with cheaper insulin

    (Reuters) – Drugmaker Eli Lilly announced.

  • Ebola treatment centre in Congo reopens after attack – ministry

    KINSHASA (Reuters) – An Ebola treatment.

  • Quebec appeals court upholds C$15 billion tobacco class action ruling

    MONTREAL/LONDON (Reuters) – The Court of.

  • Gastric bypass surgery tied to diabetes remission

    (Reuters Health) – Three in four.

  • After attacks, MSF suspends Ebola treatment in epicenter of Congo outbreak

    DAKAR (Reuters) – Medecins Sans Frontieres.

  • Yoga linked to lowered blood pressure with regular practice

    (Reuters Health) – Adults who practice.